May Patients Receiving 5-Alpha-Reductase Inhibitors Be at Higher Risk of COVID-19 Complications?
April 2020
in “
Medical hypotheses
”
Studysummary This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on sciencedirect.com →